This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Oculus Innovative Sciences Announces Licensing Of Microcyn(R)-Based Products In Mexico, South/Central America And Caribbean Countries To More Pharma With $5.1 Million Up Front Payment

  • Sales in Mexico to Transition to More Pharma's 200-Plus Person Marketing and Sales Team Immediately
  • Expansion into South/Central American and Caribbean Countries as Regulatory Approvals Secured
  • Joint Conference Call: August 14, 2012 at 8 am PDT to Discuss Details of Partnership

MEXICO CITY and PETALUMA, Calif., Aug. 9, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), innovator and developer of products based upon the Microcyn® Technology platform, announced today the exclusive licensing of the company's Microcyn-based human healthcare products in Mexico, South/Central America and the Caribbean to More Pharma Corporation, a 300-plus person pharmaceutical company with a commercial presence in Mexico, South/Central America and the Caribbean ( www.morepharmacorp.com/eng/compania.php ).

Guillermo Ibarra, More Pharma's CEO said, "Since our founding in 2007, More Pharma has established a track record of strong growth because of our ability to identify and partner with cutting edge pharmaceutical technologies. We believe the Microcyn Technology—already proven and with a dominant share of the Mexican market—is a compelling addition to our product portfolio, allowing us to build upon Oculus' established success in the Mexican market and affording us the opportunity to achieve similar commercial success throughout the South and Central American and Caribbean countries." 

Under the terms of the agreement, More Pharma will pay Oculus an upfront $5.1 million licensing fee. The transition of the marketing and sales effort in Mexico to More Pharma will begin immediately, while expansion into other South/Central American and Caribbean countries is dependent upon securing the needed regulatory clearances in those regions. More Pharma will oversee and underwrite all costs for regulatory review and approval.    

Hoji Alimi, CEO of Oculus, said, "We are excited about partnering with More Pharma and their rapidly growing sales and marketing teams in Mexico, the Caribbean, Central and South America.  We believe this positions us for accelerated long-term unit sales growth in Mexico and also provides us with a terrific partner to introduce our portfolio of Microcyn-based products throughout South and Central America—new territories that are large, untapped markets with a growing middle class."

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,563.30 -317.06 -1.88%
S&P 500 1,930.67 -39.40 -2.00%
NASDAQ 4,369.7730 -93.1290 -2.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs